Etarfolatide Molecular Imaging
Designed to identify tumors that may respond to folate-targeted therapy
Etarfolatide is a folate-targeted molecular imaging agent that is being developed to non-invasively identify tumors that express folate receptors and that may respond to folate-targeted therapy. It is being developed as the companion imaging agent to EC1456 (folate-tubylysin).
Etarfolatide imaging has been a component in more than 20 clinical studies in patients with cancers of the ovary, endometrium, kidney, pituitary, lung, and refractory solid tumors; and has been administered to more than 1400 patients.
* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.